Top Qs
Timeline
Chat
Perspective

JPC0323

Pharmaceutical compound From Wikipedia, the free encyclopedia

Remove ads

JPC0323, also known as N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)oleamide, is a dual serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator related to oleamide.[1][2] It showed negligible affinity for roughly 50 other targets and did not bind to the orthosteric sites of these receptors.[1][2] The drug does not affect the serotonin 5-HT2B receptor.[1][2]

Quick Facts Clinical data, Other names ...

JPC0323 showed favorable pharmacokinetic properties in preclinical research.[1][2] It produced hypolocomotion in a serotonin 5-HT2C receptor-dependent but not serotonin 5-HT2A receptor-dependent manner in rats, suggesting that it might be a preferential serotonin 5-HT2C receptor positive allosteric modulator in vivo.[1][2] The drug was not assessed in terms of head-twitch response, an animal behavioral proxy of psychedelic effects.[2] It is unknown whether it might have hallucinogenic effects via serotonin 5-HT2A receptor potentiation, but its developers speculated that it might have reduced potential in this regard compared to orthosteric agonists.[2]

JPC0323 was derived as an analogue of the fatty acid amide oleamide and was first described in the scientific literature by 2023.[1][2] It was described as a "first-in-class" dual serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator.[2]

Remove ads

See also

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads